Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

5.71
+0.34006.33%
Pre-market: 5.62-0.0900-1.58%07:16 EST
Volume:1.19M
Turnover:6.68M
Market Cap:794.40M
PE:-1.58
High:5.74
Open:5.35
Low:5.33
Close:5.37
52wk High:14.45
52wk Low:4.16
Shares:139.13M
Float Shares:94.55M
Volume Ratio:0.79
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6228
EPS(LYR):-3.8310
ROE:-49.06%
ROA:-25.97%
PB:1.00
PE(LYR):-1.49

Loading ...

Barclays Sticks to Their Buy Rating for Vir Biotechnology (VIR)

TIPRANKS
·
7 hours ago

Stock Track | Vir Biotechnology (VIR) Soars 5.03% as Analysts Maintain Buy Ratings

Stock Track
·
17 hours ago

Stock Track | Vir Biotechnology (VIR) Soars 5.03% on Bullish Analyst Ratings

Stock Track
·
17 hours ago

Morgan Stanley Sticks to Its Buy Rating for Vir Biotechnology (VIR)

TIPRANKS
·
Yesterday

Vir Biotechnology (VIR) Gets a Buy from TD Cowen

TIPRANKS
·
Yesterday

Some Analysts Just Cut Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates

Simply Wall St.
·
Nov 10

Stock Track | Vir Biotechnology Surges 11.11% Pre-market on Promising Hepatitis Delta Treatment Results

Stock Track
·
Nov 10

Stock Track | Vir Biotechnology Soars 8.38% on Positive Phase 2 Results for Hepatitis Delta Treatment

Stock Track
·
Nov 10

Stock Track | Vir Biotechnology Soars 8.38% on Positive Phase 2 Results for Hepatitis Delta Treatment

Stock Track
·
Nov 10

Vir Biotechnology announces Week 48 endpoint analysis of Phase 2 SOLSTICE

TIPRANKS
·
Nov 10

Vir Biotechnology Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta

Reuters
·
Nov 10

Vanina de Verneuil, EVP and General Counsel, Reports Sale of Vir Biotechnology Common Shares

Reuters
·
Nov 08

Vir Biotechnology to Present at Jefferies London Healthcare Conference

Reuters
·
Nov 07

Evercore ISI Remains a Buy on Vir Biotechnology (VIR)

TIPRANKS
·
Nov 06

Bank of America Securities Sticks to Their Buy Rating for Vir Biotechnology (VIR)

TIPRANKS
·
Nov 06

Vir Biotechnology misses Q3 revenue estimates

Reuters
·
Nov 06

Vir Biotechnology Q3 EPS $(1.17) Misses $(0.84) Estimate, Sales $240.000K Miss $1.983M Estimate

Benzinga
·
Nov 06

Vir Biotechnology Reports Strong Q3 Results and Advances Clinical Pipeline

Reuters
·
Nov 06

BRIEF-Vir Biotechnology Q3 EPS USD -1.17

Reuters
·
Nov 06

Director Vicki L. Sato Reports Sale of Vir Biotechnology Inc. Common Shares

Reuters
·
Nov 05